From GlobeNewswire: 2025-04-16 16:04:00

Bavarian Nordic A/S receives recommendation by the Advisory Committee on Immunization Practices (ACIP) to recommend VIMKUNYA™ for the prevention of chikungunya virus disease for individuals aged 12 and older. This expands access for American travelers to countries with outbreaks or heightened risk of chikungunya. The CDC reports chikungunya cases in over 50 countries in the last five years. VIMKUNYA is a single-dose vaccine approved by the FDA and the European Commission for individuals aged 12 and older. Additional clinical studies are required to confirm the clinical profile of VIMKUNYA. Safety information regarding allergies and potential side effects is provided.



Read more at GlobeNewswire: Bavarian Nordics chikungunyavaccine modtager anbefaling af